{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:26Z","timestamp":1787020106553,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Hope Run Special Fund of Cancer Foundation of China","award":["No.LC2018L03"],"award-info":[{"award-number":["No.LC2018L03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastric cancer ranks high in terms of morbidity and mortality worldwide. Multimodal therapy is therefore essential for locally advanced gastric cancer. Recent studies have demonstrated that both perioperative chemotherapy and neoadjuvant chemoradiotherapy can improve the prognosis of patients. However, the completion rate of chemotherapy after surgery remains low, which may affect survival. Thus, identifying the best way to combine radiotherapy, chemotherapy and surgery is important. The aim of this study was to explore the toxicity and efficacy of the total neoadjuvant therapy modality for locally advanced gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study will be a prospective, multicenter, single-arm, phase II clinical trial. Patients diagnosed with locally advanced (stage cT3-4 and cN positive, AJCC 8th) gastric cancer\u00a0and gastroesophageal junction adenocarcinoma will be enrolled. Patients will initially receive radiotherapy (95% planned target volume: 45\u00a0Gy\/25\u00a0f) and concurrent chemotherapy (S-1: 40\u201360\u00a0mg twice a day) followed by six cycles of consolidated chemotherapy (SOX, consisting of S-1 and oxaliplatin) and surgery. The primary objective will assess pathological complete response; the secondary objectives will include toxicities assessing surgical complications, the tumor downstaging rate and the R0 resection rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Investigation of total neoadjuvant therapy in gastric cancer is limited. The goal of this trial is to explore the efficacy and toxicity of total neoadjuvant therapy for locally advanced gastric\u00a0cancer and gastroesophageal junction adenocarcinoma.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : Clinicaltrials.gov (NCT04062058, August 20, 2019).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-022-02440-5","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T05:05:32Z","timestamp":1658984732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct04062058","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jinming","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"issue":"12","key":"2440_CR1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2014-308915","volume":"64","author":"A Colquhoun","year":"2015","unstructured":"Colquhoun A, Arnold M, Ferlay J, et al. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881\u20138.","journal-title":"Gut"},{"issue":"2","key":"2440_CR2","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA: Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA: Cancer J Clin"},{"issue":"1","key":"2440_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12957-016-1042-y","volume":"14","author":"D Liu","year":"2016","unstructured":"Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14(1):305\u201316.","journal-title":"World J Surg Oncol"},{"issue":"19","key":"2440_CR4","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","volume":"30","author":"SR Smalley","year":"2012","unstructured":"Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327\u201333.","journal-title":"J Clin Oncol"},{"key":"2440_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.017","author":"SH Park","year":"2020","unstructured":"Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2020. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.017.","journal-title":"Ann Oncol"},{"issue":"06","key":"2440_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4236\/jct.2018.96041","volume":"09","author":"S Ahmed","year":"2018","unstructured":"Ahmed S, Fawzy M, Rezk K, et al. Preoperative conformal radiotherapy concurrently with paclitaxel\/carboplatin in gastric cancer. J Cancer Ther. 2018;09(06):503\u201315.","journal-title":"J Cancer Ther"},{"issue":"9","key":"2440_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090\u20138.","journal-title":"Lancet Oncol"},{"issue":"10184","key":"2440_CR8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"1","key":"2440_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"13","key":"2440_CR10","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715\u201321.","journal-title":"J Clin Oncol"},{"key":"2440_CR11","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer, V.2.2021. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"issue":"5","key":"2440_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","volume":"19","author":"A Cats","year":"2018","unstructured":"Cats A, Jansen EPM, Van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616\u201328.","journal-title":"Lancet Oncol"},{"key":"2440_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","volume":"81","author":"M Stahl","year":"2017","unstructured":"Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer. 2017;81:183\u201390.","journal-title":"Eur J Cancer"},{"issue":"11","key":"2440_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","volume":"85","author":"JR Siewert","year":"1998","unstructured":"Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457\u20139.","journal-title":"Br J Surg"},{"issue":"2","key":"2440_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.radonc.2009.03.018","volume":"92","author":"O Matzinger","year":"2009","unstructured":"Matzinger O, Gerber E, Bernstein Z, et al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol. 2009;92(2):164\u201375.","journal-title":"Radiother Oncol"},{"issue":"2","key":"2440_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 3rd English edition. Gastric Cancer. 2011;14(2):101\u201312.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2440_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0167-8140(02)00140-8","volume":"64","author":"JC Stroom","year":"2002","unstructured":"Stroom JC, Heijmen BJ. Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report. Radiother Oncol. 2002;64(1):75\u201383.","journal-title":"Radiother Oncol"},{"issue":"2","key":"2440_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"11","key":"2440_CR19","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680\u20136.","journal-title":"Cancer"},{"issue":"3","key":"2440_CR20","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.ijrobp.2018.06.057","volume":"102","author":"X Wang","year":"2018","unstructured":"Wang X, Jin J, Zhao DB, et al. A randomized phase II trial of neoadjuvant chemotherapy compared with chemoradiotherapy in locally advanced gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2018;102(3):S29\u201330.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2440_CR21","first-page":"128","volume":"24","author":"Y Tian","year":"2021","unstructured":"Tian Y, Wang Q, Wang J, et al. Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial]. Zhonghua Wei Chang Wai Ke Za Zhi. 2021;24(2):128\u201337.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"4","key":"2440_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jso.24917","volume":"117","author":"X Liu","year":"2018","unstructured":"Liu X, Li G, Long Z, et al. Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer. J Surg Oncol. 2018;117(4):692\u20138.","journal-title":"J Surg Oncol"},{"key":"2440_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.radonc.2019.06.029","volume":"140","author":"HS Kim","year":"2019","unstructured":"Kim HS, Koom WS, Baek SE, et al. Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. Radiother Oncol. 2019;140:143\u20139.","journal-title":"Radiother Oncol"},{"issue":"8","key":"2440_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081\u201392.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2440_CR25","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1245\/s10434-017-5830-6","volume":"24","author":"T Leong","year":"2017","unstructured":"Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017;24(8):2252\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2440_CR26","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-019-5728-8","volume":"19","author":"X Liu","year":"2019","unstructured":"Liu X, Jin J, Cai H, et al. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer. 2019;19(1):606.","journal-title":"BMC Cancer"},{"issue":"1","key":"2440_CR27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1186\/s12885-018-4770-2","volume":"18","author":"AE Slagter","year":"2018","unstructured":"Slagter AE, Jansen EPM, Van Laarhoven HWM, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18(1):877.","journal-title":"BMC Cancer"},{"issue":"2","key":"2440_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10120-018-0901-3","volume":"22","author":"F Petrelli","year":"2019","unstructured":"Petrelli F, Ghidini M, Barni S, et al. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Gastric Cancer. 2019;22(2):245\u201354.","journal-title":"Gastric Cancer"},{"issue":"24","key":"2440_CR29","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1200\/JCO.2006.06.4840","volume":"24","author":"JA Ajani","year":"2006","unstructured":"Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953\u20138.","journal-title":"J Clin Oncol"},{"issue":"06","key":"2440_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4236\/jct.2018.96041","volume":"09","author":"S Ahmed","year":"2018","unstructured":"Ahmed S, Fawzy M, Rezk K, Elshrif W, Alaa M, Ellah MMHA. Preoperative conformal radiotherapy concurrently with paclitaxel\/carboplatin in gastric cancer. J Cancer Ther. 2018;09(06):503\u201315.","journal-title":"J Cancer Ther"},{"issue":"6","key":"2440_CR31","doi-asserted-by":"publisher","first-page":"e180071","DOI":"10.1001\/jamaoncol.2018.0071","volume":"4","author":"A Cercek","year":"2018","unstructured":"Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2440_CR32","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.ijrobp.2019.06.554","volume":"105","author":"JY Wo","year":"2019","unstructured":"Wo JY, Clark JW, Roeland E, et al. A pilot study of neoadjuvant FOLFIRINOX FOLLOWED by chemoradiation for gastric and gastroesophageal cancer: preliminary results and prognostic implications of ctDNA. Int J Radiat Oncol Biol Phys. 2019;105(1):S85\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2440_CR33","first-page":"1204","volume":"25","author":"X Wang","year":"2016","unstructured":"Wang X, Zhao DB, Jin J, et al. A preliminary study of efficacy of preoperative concurrent chemoradiotherapy for locally advanced gastric cancer. Chin J Radiat Oncol. 2016;25(11):1204\u20138.","journal-title":"Chin J Radiat Oncol"},{"issue":"1","key":"2440_CR34","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","volume":"11","author":"BK Sah","year":"2020","unstructured":"Sah BK, Zhang B, Zhang H, et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11(1):6093.","journal-title":"Nat Commun"},{"issue":"3","key":"2440_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/ajco.13321","volume":"16","author":"Z Jiang","year":"2020","unstructured":"Jiang Z, Sun Y, Zhang W, et al. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: a single-center retrospective study. Asia Pac J Clin Oncol. 2020;16(3):180\u20136.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"2440_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12885-020-07764-7","volume":"21","author":"X Wang","year":"2021","unstructured":"Wang X, Li S, Sun Y, et al. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer. 2021;21(1):20.","journal-title":"BMC Cancer"},{"issue":"8","key":"2440_CR37","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang FH, Zhang XT, Li YF, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 2021;41(8):747\u201395 (London).","journal-title":"Cancer Commun"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02440-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T16:05:32Z","timestamp":1659024332000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02440-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2440"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02440-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was obtained for this trial from the ethical committee of the Chinese Academy of Medical Sciences. The trial is published on ClinicalTrials.gov (number: NCT04062058,\n                      \n                      ). Written informed consent is obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}